Merrimack to scrap development of pancreatic cancer treatment

(Reuters) - Merrimack Pharmaceuticals Inc said on Monday it would discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.